Organisation paid for research Program year 2024 Source: CMS Open Payments

Arp Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$193,596

97 payments

Through program year 2024, Arp Research Group LLC is reported as receiving $193,596 in research payments, across 97 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$4,198	2
2023	Research	$5,574	10
2022	Research	$6,864	9
2021	Research	$43,867	29
2020	Research	$59,877	25
2019	Research	$73,215	22

Breakdown

Who paid Research payments · program years 2019–2024

AbbVie, Inc. $193,596 97 payments

Studies the money was for Research payments · program years 2019–2024

M14-702 $83,691 25 payments
M16-283 $38,901 21 payments
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $19,642 8 payments
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain $16,984 11 payments
M18-969 $10,500 1 payment
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $7,241 10 payments
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $5,776 7 payments
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $5,574 10 payments
Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $4,198 2 payments
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $1,089 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.